MoonLake Immunotherapeutics (NASDAQ:MLTX) Upgraded at Rothschild & Co Redburn

Rothschild & Co Redburn upgraded shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) from a neutral rating to a buy rating in a research note published on Thursday, Marketbeat reports. The firm currently has $40.00 price target on the stock, up from their prior price target of $12.00.

Other equities analysts have also recently issued research reports about the company. The Goldman Sachs Group cut MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and increased their target price for the company from $8.00 to $10.00 in a report on Wednesday, January 14th. Zacks Research raised MoonLake Immunotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. BTIG Research boosted their price target on MoonLake Immunotherapeutics from $24.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, February 23rd. UBS Group set a $24.00 price objective on MoonLake Immunotherapeutics in a research note on Friday, January 9th. Finally, Royal Bank Of Canada raised their price objective on MoonLake Immunotherapeutics from $12.00 to $13.00 and gave the company a “sector perform” rating in a report on Monday, March 2nd. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $25.92.

MoonLake Immunotherapeutics Stock Down 2.5%

Shares of NASDAQ MLTX opened at $16.27 on Thursday. The company’s 50-day simple moving average is $16.84 and its 200-day simple moving average is $19.12. MoonLake Immunotherapeutics has a 52-week low of $5.95 and a 52-week high of $62.75. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of -4.62 and a beta of 1.20. The company has a quick ratio of 9.27, a current ratio of 9.27 and a debt-to-equity ratio of 0.24.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, February 25th. The company reported ($0.92) EPS for the quarter, hitting analysts’ consensus estimates of ($0.92). During the same quarter in the previous year, the firm posted ($0.72) EPS. Equities analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Institutional Trading of MoonLake Immunotherapeutics

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in shares of MoonLake Immunotherapeutics by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 59,553 shares of the company’s stock worth $2,809,000 after acquiring an additional 559 shares during the last quarter. Squarepoint Ops LLC increased its holdings in MoonLake Immunotherapeutics by 3.7% in the 2nd quarter. Squarepoint Ops LLC now owns 17,571 shares of the company’s stock valued at $829,000 after purchasing an additional 629 shares during the last quarter. Axiom Investors LLC DE increased its holdings in MoonLake Immunotherapeutics by 3.2% in the 4th quarter. Axiom Investors LLC DE now owns 25,998 shares of the company’s stock valued at $343,000 after purchasing an additional 818 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in MoonLake Immunotherapeutics by 45.4% in the 4th quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock valued at $45,000 after purchasing an additional 1,069 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in MoonLake Immunotherapeutics by 18.9% in the third quarter. BNP Paribas Financial Markets now owns 7,296 shares of the company’s stock valued at $52,000 after purchasing an additional 1,158 shares during the period. Hedge funds and other institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.